Management and Board of Directors

TODD ZION, Ph.D.

PRESIDENT & CEO, CHAIRMAN OF THE BOARD
Dr. Zion was President and CEO of SmartCells, Inc., developer of SmartInsulin, from its founding through its sale to Merck & Co., Inc. in 2010. He earned his doctorate in Chemical Engineering at the Massachusetts Institute of Technology. At M.I.T., Todd won the Robert P. Goldberg Grand Prize in the 2003 M.I.T. $50K Entrepreneurship competition. Prior to enrolling at M.I.T., he worked as a polymer development engineer at Eastman Kodak. Todd graduated from Cornell University summa cum laude with a B.S. in Chemical Engineering.

THOMAS LANCASTER, Ph.D.

VICE PRESIDENT, MANUFACTURING AND PRODUCT RESEARCH AND DEVELOPMENT, DIRECTOR
Dr. Lancaster was Vice President of Research and Development at SmartCells, Inc. from 2004 through its sale to Merck & Co., Inc. in 2010. Dr. Lancaster earned his Ph.D. in Chemical Engineering at the Massachusetts Institute of Technology where he was an NSF Graduate Fellow and an Elf Autochem Fellow. Before entering M.I.T., he was a Research Engineer at Union Carbide Corporation. Tom graduated with high distinction from Pennsylvania State University with a B.S. in Chemical Engineering.

THILLAINAYGAM SATHIYASEELAN, Ph.D.

VICE PRESIDENT, QUALITY AND REGULATORY AFFAIRS
Dr. Sathiyaseelan (“Sathi”) was Director of Bioanalytical Development at SmartCells, Inc. at the time of its sale to Merck & Co. in 2010. Before that, he was Senior Manager, Vaccine Preclinical Development Projects at Vaxine Pty Ltd, Adelaide, Australia and Director (Immunology R&D and Therapeutic Antibody Development) at Hematech Inc., Sioux Falls, SD. Sathi earned his Ph.D. in Immunology from the University of Massachusetts, Amherst and his Bachelor of Veterinary Medicine & Surgery degree from the University of Peradeniya, Sri Lanka.

JAMES HERRIMAN

VICE PRESIDENT, OPERATIONS
Mr. Herriman was Vice President of Operations of SmartCells, Inc. from 2004 through its sale to Merck & Co., Inc. in 2010. He was Vice President of Product Development at Neuromedical Systems, Inc. where he played a key role in helping to grow this start-up to a $100 million NASDAQ IPO, was a co-founder and President of Aspex Incorporated and Vice President of Operations at Media-Unbound, Inc., which was acquired by Rovi Corporation. Jim received his B.A. in Philosophy from Emory University.

ED CANNON, Ph.D.

DIRECTOR
Dr. Cannon is currently the founder, President and CEO of NovAb, Inc., which is developing a novel class of antibody biotherapeutics. He was formerly the President and CEO of Unigen Pharmaceuticals, the CEO of AerovectRx, the President and CEO of AdipoGenix; the founding CEO of Elixir Pharmaceuticals; a founder, director, and President of the Therapeutics Division of DyaxCorp and a founder, director and CSO of Hygeia Sciences. Ed earned his Ph.D. in biochemistry from the University of Georgia, trained in molecular immunology at Harvard Medical School and has held faculty positions at Brandeis University and University of Massachusetts Medical School.

ROBYN DAVIS

DIRECTOR
Ms. Davis is currently a Director at Brooks Automation (BRKS),  a leading provider of life science solutions, genomic services and semiconductor equipment and a Director at CRA Health, a comprehensive cancer risk assessment firm.  Ms. Davis is a Managing Director of AngelHealthcare Investors and Executive Coach at The Leadership Consortium. Ms. Davis has also advised many global clients on strategy and organizational issues and earned her B.A. from Tufts University and her M.B.A. from Harvard University.

Advisors

GARY P. MAGNANT

Gary Magnant is currently a General Partner at Formation Venture Engineering Fund II and co-founder of FVE Foundry. Mr. Magnant has had a long and successful career as a founder and executive of life sciences companies. He was a co-founder and is the former CEO of Thrive Bioscience, Inc., Sage Science, Inc., and Owl Scientific (now part of Thermo Fisher). Gary was a co-founder and President of ActivBiotics and ThermoCeramix. He is also the former Chairman, Trustee, and Hallowell Awardee of Stoneridge, a private Montessori school in Beverly, MA. Gary holds a Master’s of Science degree in Microbiology from Montana State University.

HORACE NALLE

Horace Nalle is General Counsel to Argenta, the global veterinary contract research, development, and manufacturing organization, Nalle is a principal in Oriole Advisors, which provides business and transactional advice to companies and investors in animal health. Previously, Mr. Nalle was the CEO of Hubbard ISA, the global avian genetics firm. Mr. Nalle held various C-suite positions at the global animal health company now known as Boehringer Ingelheim Vetmedica, including CLO, Head of Communications and Public Affairs, Head of Regulatory Affairs, and Head of Blue Sky Research. He earned a Bachelor’s degree in government from Harvard University and a Juris Doctor from the University of Pennsylvania Law School. He is Of Counsel to Akston.

RASHMI BARBHAIYA, Ph.D.

Dr. Barbhaiya is a pharmaceutical executive with more than 30 years’ experience in pharmaceutical R&D, over twenty years in large pharma and the last ten years as an entrepreneur. Rashmi is one of the founders and was CEO and Managing Director of Advinus Therapeutics, a research-based pharma company located in Bangalore and Pune, India. He was President of R&D at Ranbaxy and a Vice President at Bristol-Myers Squibb. He earned his Ph.D. in Clinical Pharmacology from the St. Bartholomew’s Hospital Medical College, University of London, with post-doctoral training at the University of Florida and University of Wisconsin. He is an author of over 150 publications in peer reviewed journals.